Qinqin Hu

Dose tapering to withdrawal stage and long‐term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open‐label extension study

Jing Liu, Jianda Hu, Y. Li, 2021, Journal of thrombosis and haemostasis : JTH.

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

Jing Liu, Jie Jin, Jianda Hu, 2021, Journal of Hematology & Oncology.